Research Comparison
CJC-1295 (without DAC) vs IGF-1 LR3 (Long R3 IGF-1)
A side-by-side research comparison of CJC-1295 (without DAC) and IGF-1 LR3 (Long R3 IGF-1) drawn from Cobalt Peptides' peptide database records.
CJC-1295 (without DAC)
CJC-1295 (without DAC), also known as Modified GRF 1-29 (Mod GRF 1-29), is a short-acting synthetic analog of growth hormone releasing hormone (GHRH). It is designed to stimulate endogenous growth hormone (GH) release in a pulsatile, physiologically consistent manner. Unlike the DAC-modified version, this variant has a very short half-life, allowing precise control over GH pulses and reducing the risk of receptor desensitization. It is primarily used in research focused on recovery, anti-aging, body composition, and endocrine function optimization.
IGF-1 LR3 (Long R3 IGF-1)
IGF-1 LR3 is a synthetic 83-amino acid analog of insulin-like growth factor-1 (IGF-1), modified with an arginine substitution at position 3 and an extended N-terminal sequence. These modifications significantly reduce binding to IGF-binding proteins (IGFBPs), resulting in prolonged circulation and increased bioavailability. Unlike native IGF-1, which has a short half-life, IGF-1 LR3 exhibits a substantially extended half-life (~20–30 hours), allowing sustained activation of IGF-1 receptors. Despite its potency and widespread research use, it has never been approved for human use and lacks clinical trial data, remaining strictly a research compound.